GenomIQ – The Think Tank Behind Integrity Laboratories

For decades, scientific research has seen a decline in out-of-the-box thinking. Instead, scientists have focused on more restrictive, linear, often sequential reasoning resulting in smaller but thoughtful technical advancements.

In a strange turn of events, ‘innovation’ in science has become more about how to optimize the wheel rather than revolutionize the way things move.

Yet true innovation requires creative problem-solving skills. We have seen this in progressive technology and engineering feats – where Steve Jobs took what was considered the gold standard of computers and redefined it with his Macintosh. Apple is now known as a true innovative leader for that reason. They are constantly exploring the idea of intuitive technology and focusing on deliberate, intentional innovation. Integrity Laboratories uses this same strategy to cultivate thoughtful diagnostic technology that supports avant-garde scientific ingenuity.

In the realm of science, innovative research confronts more rigid guidelines – and sometimes, even science needs a revolution.

When Integrity Laboratories was founded, we were devoted to the idea of extending lives and restoring the health of the world. But we weren’t the first – nor the last – to commit to this endeavor. Rather than optimize the wheel, we decided to start over and redefine the standard approach in diagnostic testing.

As Albert Einstein once said, “Creativity is intelligence having fun,” To drive true innovation, we must extend ourselves past traditional thinking and tap into the creativity of limitless possibilities.

And GenomIQ, the research and development arm of Integrity Laboratories, is facing a new evolution within our humble origins. Now, we’re dedicating new resources to optimizing our fully integrated but autonomous initiative focused on increasing the collaboration between creativity and science.

As our answer to an in-house applied science incubator, GenomIQ is focused on expanding creative innovation in the fields of infectious and non-infectious disease research. Founded upon the principles of design thinking, GenomIQ uses deliberate and intentional innovation rather than innovation for innovation’s sake.

These driving forces exemplified their potential when we sought to rapidly develop emergency COVID-19 diagnostic testing. Powered by a collaborative team of science professionals, we were able to assemble and accelerate an FDA approved test in only 6 weeks.

Now, we are expanding GenomIQ’s initiative to improve the opportunity of more meaningful diagnostic and therapeutic areas outside of infectious disease.

Integrity Laboratories is diversifying our role and taking a stronger stance in establishing greater innovation of infectious disease technology in our region through GenomIQ.” says Dr. Cekanova, Chief Scientific Officer at Integrity Laboratories.

Headed by Dr. Maria Cekanova, CSO of Integrity Laboratories, GenomIQ is now supporting a new 5-7 year roadmap outlining new areas of innovation. We have spent years cultivating relationships and building our network – now it’s time to leverage it.

Over the coming months, we’ll be making some exciting new announcements about where we’re going. Integrity Laboratories is growing to help support our region and improve its efforts in re-establishing a creative collective toward scientific innovation.

Integrity Laboratories began testing for SARS-CoV-2 (COVID-19) under Emergency Use Authorization (EUA) on March 23.

Please direct all inquiries to for immediate review.

Click Here for CDC recommendations for Identifying Monkeypox.

FDA Authorization Letter   |   FDA EUA Summary

CARES Act Statement